MKI67 and small cell carcinoma: Reclassification under the WHO 2022 criteria would correspond to a small cell neuroendocrine carcinoma (25 mitoses per 2 mm2 and a Ki67 index of 50%), with focal ACTH positivity in both the liver lesion and metastatic nodes.